7 clinical trials found.
-
Genentech- CA41705 - new study CDA
The purpose of this study is to compare the effects, good or bad, of the study drug called obinutuzumab (also known as Gazyva or Gazyvaro ... -
A novel Phase 2 double-blind randomized controlled clinical trial to evaluate the efficacy of centrally acting non-toxic ACE inhibition in cognitive impairment associated with SLE
This research study is being done to test the effects of centrally-acting ACE inhibitor, named lisinopril, on resting metabolism in the brain and on cognitive ... -
A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (POTEYK-SLE-1)
Researchers hope to learn more about whether deucravacitinib can help in the treatment of SLE and how safe it is to use in people with ... -
A Phase 1 Multicenter Open-Label Study Of CC-97540 (BMS-986353) CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells in Participants with Severe Refractory Systemic Lupus Erythematosus (SLE)
This study will enroll participants with SLE who have a severe, life-threatening disease course and have been refractory to currently available therapies. Because of the ... -
SAMPLE (Specimen and Matched Phenotype Linked Evaluation)
Researchers at NYU have developed a clinical registry containing information related to the patient’s ethnicity, race, gender, age, medications, specific disease or state of ... -
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly
Fetal complete (i.e., third degree) atrioventricular block (AVB), identified in the 2nd trimester of pregnancy in an otherwise normally developing heart, is almost universally ... -
An Evaluation of Home Urinalysis Testing for Systemic Lupus Erythematosus (SLE) Patients at Elevated Risk for Developing Lupus Nephritis: A Pilot Stage and Randomized Controlled Study
In this pilot study participants who enrolled in the SAMPLE Biorepository (s14-00487), who have provided permission to be contacted for future research, will be invited ...
